tovorafenib
Selected indexed studies
- The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. (Nat Med, 2024) [PMID:37978284]
- Tovorafenib: First Approval. (Drugs, 2024) [PMID:38967715]
- LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. (BMC Cancer, 2024) [PMID:38291372]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. (2024) pubmed
- Tovorafenib: First Approval. (2024) pubmed
- LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. (2024) pubmed
- Tovorafenib. (2006) pubmed
- Tovorafenib. (2012) pubmed
- FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma. (2025) pubmed
- Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma. (2024) pubmed
- How will tovorafenib change our treatment of pediatric low-grade glioma? (2024) pubmed
- Tovorafenib (Ojemda) for pediatric low-grade glioma. (2024) pubmed
- Tovorafenib effective against low-grade gliomas harbouring BRAF fusions. (2024) pubmed